Skip to main content

Table 3 Disease detection, colposcopies needed, and false positive (negative) rates of different triage strategies (N = 2731)

From: Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China

Triage strategies

Number of colposcopies

CRR (%)

Number of CIN2+/ CIN3+ detected

NRND for CIN2+/CIN3+

FPR (%)

for CIN2+

FNR (%) for CIN2+

Single test

 1.p16+

698

25.6

113/42

6.2/16.6

22.5

16.9

 2.HPV16+

624

22.8

85/46

7.3/13.6

20.8

37.5

 3.HPV16/33+

756

27.7

92/48

8.2/15.8

25.6

32.4

 4.HPV16/33/58+

1094

40.1

106/50

10.3/21.9

38.1

22.1

 5.HPV16/33/58/31+

1240

45.4

111/50

11.2/24.8

43.5

18.4

 6.HPV16/33/58/31/35+

1301

47.6

113/50

11.5/26.0

45.8

16.9

7.HPV16/18 + (comparator)

888

32.5

93/49

9.5/18.1

30.6

31.6

 8.HPV16/18/31/33/45/52/58+

1885

69.0

125/52

15.1/36.3

67.8

8.1

HPV types + or p16+

 9.HPV16+ or p16+

1049

38.4

127/52

8.3/20.2

35.5

6.6

 10.HPV16/33+ or p16+

1150

42.1

128/52

9.0/22.1

39.4

5.9

 11.HPV16/33/58+ or p16+

1406

51.5

132/53

10.7/26.5

49.1

2.9

 12.HPV16/33/58/31+ or p16+

1522

55.7

132/53

11.5/28.7

53.6

2.9

 13.HPV16/33/58/31/35+ or p16+

1570

57.5

132/53

11.9/29.6

55.4

2.9

 14.HPV16/18+ or p16+

1219

44.6

129/53

9.4/23.0

42.0

5.1

 15.HPV16/18/31/33/45/52/58+ or p16+

2007

73.5

133/53

15.1/37.9

72.2

2.2

HPV types + & p16+

 16.HPV16+ or HPV33/58/31/35 + &p16+

780

28.6

108/49

7.2/15.9

25.9

20.6

 17.HPV16/33+ or HPV58/31/35 + &p16+

881

32.3

109/49

8.1/18.0

29.7

19.9

 18.HPV16/33/58/31/35 + &p16+

429

15.7

94/39

4.6/11.0

12.9

30.9

 19.HPV16/18/31/33/45/52/58 + &p16+

576

21.1

105/41

5.5/14.0

18.2

22.8

  1. CRR Colposcopy referral rate, NRND The number of referrals needed to detect one case, FPR False positive rate = 1-specificity, proportion of index test positives among histologic normal results (cervical intraepithelial neoplasia grade 1 or less), FNR False negative rate = 1-sensitivity, proportion of index test negatives among histologic abnormal results (CIN2+)